The prevalence of vascular and metabolic complications after lung transplant in people with cystic fibrosis in a Dutch cohort.
Cystic fibrosis
Diabetes
Lung transplant
Metabolic disease
Renal insufficiency
Vascular disease
Journal
Clinics (Sao Paulo, Brazil)
ISSN: 1980-5322
Titre abrégé: Clinics (Sao Paulo)
Pays: United States
ID NLM: 101244734
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
04
2023
revised:
28
06
2023
accepted:
28
07
2023
medline:
24
8
2023
pubmed:
20
8
2023
entrez:
19
8
2023
Statut:
epublish
Résumé
With improvements in care for people with Cystic Fibrosis (pwCF), total survival after Lung Transplantation (LTx) will be longer. Therefore, this population's up-to-date analysis of late-onset post-transplant metabolic and vascular complications will be more relevant in current clinical practice. We studied 100 pwCF who underwent an LTx between 2001 and 2020 at the University Medical Centre Utrecht, the Netherlands. The median age at transplant was 31 years and 55 percent was male. We assessed survival, the prevalence of metabolic complications (diabetes, renal damage, dyslipidemia, and metabolic syndrome), and vascular complications (hypertension, heart rhythm disease, micro-, and macrovascular disease). In addition, differences in risks for developing complications based on sex and overall survival were analyzed. The prevalence of macrovascular disease raised to 15.9 percent 15 years post-LTx. The prevalence of diabetes increased from 63 percent at LTx to over 90 percent 15 years post-LTx and the prevalence of dyslipidemia increased from 21 percent to over 80 percent. Survival 1-, 2-, 5-, and 10 years post-transplant were 84, 80, 76, and 58 percent respectively. No significant differences were found based on sex. This study shows that the prevalence of cardiovascular risk factors increases after LTx for CF, potentially leading to major complications. These data emphasize the necessity of regular check-ups for metabolic and vascular complications after LTx with specific attention to renal damage. Early recognition of these complications is crucial and will lead to earlier intervention, which could lead to improved prognosis after lung transplantation.
Sections du résumé
BACKGROUND
With improvements in care for people with Cystic Fibrosis (pwCF), total survival after Lung Transplantation (LTx) will be longer. Therefore, this population's up-to-date analysis of late-onset post-transplant metabolic and vascular complications will be more relevant in current clinical practice.
METHODS
We studied 100 pwCF who underwent an LTx between 2001 and 2020 at the University Medical Centre Utrecht, the Netherlands. The median age at transplant was 31 years and 55 percent was male. We assessed survival, the prevalence of metabolic complications (diabetes, renal damage, dyslipidemia, and metabolic syndrome), and vascular complications (hypertension, heart rhythm disease, micro-, and macrovascular disease). In addition, differences in risks for developing complications based on sex and overall survival were analyzed.
RESULTS
The prevalence of macrovascular disease raised to 15.9 percent 15 years post-LTx. The prevalence of diabetes increased from 63 percent at LTx to over 90 percent 15 years post-LTx and the prevalence of dyslipidemia increased from 21 percent to over 80 percent. Survival 1-, 2-, 5-, and 10 years post-transplant were 84, 80, 76, and 58 percent respectively. No significant differences were found based on sex.
CONCLUSION
This study shows that the prevalence of cardiovascular risk factors increases after LTx for CF, potentially leading to major complications. These data emphasize the necessity of regular check-ups for metabolic and vascular complications after LTx with specific attention to renal damage. Early recognition of these complications is crucial and will lead to earlier intervention, which could lead to improved prognosis after lung transplantation.
Identifiants
pubmed: 37597473
pii: S1807-5932(23)00110-2
doi: 10.1016/j.clinsp.2023.100274
pmc: PMC10460949
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100274Informations de copyright
Copyright © 2023 HCFMUSP. Published by Elsevier España, S.L.U. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflicts of interest.
Références
J Heart Lung Transplant. 2020 Jun;39(6):553-560
pubmed: 32147452
Genet Med. 2016 Jul;18(7):653-62
pubmed: 26656651
Adv Anat Pathol. 1997 Jul;4(4):265-276
pubmed: 21572890
J Cyst Fibros. 2022 Jan;21(1):18-25
pubmed: 34140249
Arch Pediatr. 2020 Feb;27 Suppl 1:eS8-eS12
pubmed: 32172939
J Heart Lung Transplant. 2015 Sep;34(9):1139-45
pubmed: 26087666
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
J Heart Lung Transplant. 2011 Feb;30(2):188-93
pubmed: 20888257
J Cyst Fibros. 2013 Jul;12(4):318-31
pubmed: 23562217
Pharmacol Res. 2018 Mar;129:95-99
pubmed: 29127059
Chest. 2012 Jul;142(1):185-191
pubmed: 22222189
J Heart Lung Transplant. 2005 Oct;24(10):1536-43
pubmed: 16210127
J Cyst Fibros. 2018 Jul;17(4):478-483
pubmed: 29187303
J Am Soc Nephrol. 2005 Sep;16(9):2557-64
pubmed: 16049069
Medicine (Baltimore). 2015 Nov;94(47):e2160
pubmed: 26632749
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Diabetes Care. 2014 Nov;37(11):2919-25
pubmed: 25193528
Transplant Proc. 2018 Dec;50(10):3732-3738
pubmed: 30577264
Transplantation. 2007 Dec 27;84(12):1701-3
pubmed: 18165784
Circ Res. 2012 Apr 13;110(8):1097-108
pubmed: 22499900
Respir Med. 1998 Jun;92(6):871-2
pubmed: 9850372
Clin Kidney J. 2019 Feb 14;12(2):258-261
pubmed: 30976406
Chest. 2011 Jun;139(6):1480-1490
pubmed: 21652558
J Cardiovasc Dev Dis. 2019 Apr 27;6(2):
pubmed: 31035613
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
Diabetes Care. 2006 Dec;29(12):2660-3
pubmed: 17130201